EBV-TCR-T cell therapy (China Immunotech)

N/A

Report date: 2024/07/16 11:54:30

Base Information

Drug NameEBV-TCR-T cell therapy (China Immunotech)
Drug Alias NameEBV-TCR-T (YT-E001) cells therapy (China Immunotech)YT-E001EBV-TCR-T (YT-E001)YT-EBV-44
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionEpstein-Barr nuclear antigen 1 modulatorsLatent membrane protein 2 modulatorsT lymphocyte replacements +[5] 
TargetsLatent membrane protein 2Epstein-Barr nuclear antigen 1Latent membrane protein 1
Therapy Area/IndicationsNasopharyngeal NeoplasmsNasopharyngeal CarcinomaEpstein-Barr Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Immunotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChina Immunotech Co LtdHebei Yanda Hospital
Inactive CompaniesN/A
Active IndicationsNasopharyngeal NeoplasmsEpstein-Barr Virus Infections
Inactive IndicationsNasopharyngeal Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A